Summary: Paul W. Estes has been promoted to president of Cognivue, Inc. Estes has been integral in the development and commercialization of Cognivue’s technology, serving most recently as the chief operating officer. 


  • Estes’ has been deeply involved in the company’s technological innovations and regulatory milestones.
  • Under Estes’ presidency, Cognivue is set to launch next-generation technologies that have already received FDA clearance.
  • Cognivue’s participation in the Bio-Hermes clinical study highlights its role in major Alzheimer’s research.

Neuroscience technology innovator Cognivue, Inc. announced that Paul W. Estes has been promoted to president, ushering in the company’s next stage of market evolution. 

Guiding Cognivue’s Future

Estes will guide the executive leadership team and oversee the company’s technology roadmap planning, new product expansion, partnership relations, sales, and staffing, the company says.

Estes’ Experience

His appointment comes after 15 years of serving in increasingly senior positions with Cognivue. Estes joined the company in 2009, helping conceive and develop Cognivue technology, then played integral roles in its de novo 510(k) clearance from the U.S. Food and Drug Administration and subsequent commercialization. Most recently, he was Cognivue’s chief operating officer. 

Estes succeeds Tom O’Neil, who left the company for a non-competitive leadership role in the healthcare infrastructure sector.

Further reading: Cognivue Launches Study to Test Cognitive Assessment Systems

“Cognivue is headed into its next chapter of success, making it an even greater privilege to lead so many incredibly talented people throughout the company. Cognivue has several exciting developments ahead, such as the full-scale launch of our FDA-cleared next-generation technologies and continued participation in the groundbreaking Bio-Hermes clinical study with the Global Alzheimer’s Platform,” says Estes. “We owe Tom a debt of gratitude for his contributions to Cognivue over the last six years. I plan to build on that momentum, with more growth to come for the benefit of our employees, partners, customers, and patients.”